Cargando…
Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2(+ )and decreased levels of IL23R(+ )CD4(+ )T - Lymphocytes in multiple sclerosis
BACKGROUND: There are a lack of biomarkers which can be used to predict clinical outcomes for multiple sclerosis (MS) patients receiving interferon beta (IFN-β). Thus the objective of this study was to characterize changes in CD4+ T-lymphocyte expression in an unbiased manner following initiation of...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292517/ https://www.ncbi.nlm.nih.gov/pubmed/22182694 http://dx.doi.org/10.1186/1471-2377-11-155 |
_version_ | 1782225289716170752 |
---|---|
author | Kress-Bennett, Jennifer M Ehrlich, Garth D Bruno, Ashley Post, J Christopher Hu, Fen Z Scott, Thomas F |
author_facet | Kress-Bennett, Jennifer M Ehrlich, Garth D Bruno, Ashley Post, J Christopher Hu, Fen Z Scott, Thomas F |
author_sort | Kress-Bennett, Jennifer M |
collection | PubMed |
description | BACKGROUND: There are a lack of biomarkers which can be used to predict clinical outcomes for multiple sclerosis (MS) patients receiving interferon beta (IFN-β). Thus the objective of this study was to characterize changes in CD4+ T-lymphocyte expression in an unbiased manner following initiation of intramuscular (IM) IFN-β-1a treatment, and then to verify those findings using marker-specific assays. METHODS: Peripheral blood specimens were collected from twenty MS patients before and after treatment with intramuscular (IM) IFN-β-1a and were used for isolation of mononuclear cells (PBMCs). mRNA expression patterns of negatively-selected CD4+ T-cells from the PBMCs were analyzed using microarray gene expression technology. IL-12 and IL-23 receptor levels on PBMC-derived CD4+ T-cells were analyzed by flow cytometry. The phosphorylation status of Stat4 was measured by performing densitometry on western blots. RESULTS: Microarray analyses demonstrated that mRNA expression of the IL-12Rβ2 gene was uniformly up-regulated in response to IFN-β-1a treatment and was associated with an increased number of IL-12Rβ2(+ )CD4(+ )T-cells by flow cytometry in 4 of 6 patients. This finding was substantiated by demonstrating that Stat4 phosphorylation, a transcription factor for IL-12, was increased after treatment. Conversely, the number of IL-23R(+ )CD4(+ )T-cells was decreased following treatment. CONCLUSIONS: The IL-12 receptor shares a common subunit, the IL-12Rβ2, with the IL-23 receptor. Both of these receptors have a probable role in regulating IL-17 and TH-17 cells, important mediators of inflammation in multiple sclerosis (MS). Thus, the changes in the numbers of CD4(+ )T-cells expressing these receptors in response to IFN-β-1a treatment may point to an important mechanism of action for this drug, but further large scale studies are needed to confirm these preliminary observations. |
format | Online Article Text |
id | pubmed-3292517 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-32925172012-03-03 Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2(+ )and decreased levels of IL23R(+ )CD4(+ )T - Lymphocytes in multiple sclerosis Kress-Bennett, Jennifer M Ehrlich, Garth D Bruno, Ashley Post, J Christopher Hu, Fen Z Scott, Thomas F BMC Neurol Research Article BACKGROUND: There are a lack of biomarkers which can be used to predict clinical outcomes for multiple sclerosis (MS) patients receiving interferon beta (IFN-β). Thus the objective of this study was to characterize changes in CD4+ T-lymphocyte expression in an unbiased manner following initiation of intramuscular (IM) IFN-β-1a treatment, and then to verify those findings using marker-specific assays. METHODS: Peripheral blood specimens were collected from twenty MS patients before and after treatment with intramuscular (IM) IFN-β-1a and were used for isolation of mononuclear cells (PBMCs). mRNA expression patterns of negatively-selected CD4+ T-cells from the PBMCs were analyzed using microarray gene expression technology. IL-12 and IL-23 receptor levels on PBMC-derived CD4+ T-cells were analyzed by flow cytometry. The phosphorylation status of Stat4 was measured by performing densitometry on western blots. RESULTS: Microarray analyses demonstrated that mRNA expression of the IL-12Rβ2 gene was uniformly up-regulated in response to IFN-β-1a treatment and was associated with an increased number of IL-12Rβ2(+ )CD4(+ )T-cells by flow cytometry in 4 of 6 patients. This finding was substantiated by demonstrating that Stat4 phosphorylation, a transcription factor for IL-12, was increased after treatment. Conversely, the number of IL-23R(+ )CD4(+ )T-cells was decreased following treatment. CONCLUSIONS: The IL-12 receptor shares a common subunit, the IL-12Rβ2, with the IL-23 receptor. Both of these receptors have a probable role in regulating IL-17 and TH-17 cells, important mediators of inflammation in multiple sclerosis (MS). Thus, the changes in the numbers of CD4(+ )T-cells expressing these receptors in response to IFN-β-1a treatment may point to an important mechanism of action for this drug, but further large scale studies are needed to confirm these preliminary observations. BioMed Central 2011-12-19 /pmc/articles/PMC3292517/ /pubmed/22182694 http://dx.doi.org/10.1186/1471-2377-11-155 Text en Copyright ©2011 Kress-Bennett et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Kress-Bennett, Jennifer M Ehrlich, Garth D Bruno, Ashley Post, J Christopher Hu, Fen Z Scott, Thomas F Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2(+ )and decreased levels of IL23R(+ )CD4(+ )T - Lymphocytes in multiple sclerosis |
title | Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2(+ )and decreased levels of IL23R(+ )CD4(+ )T - Lymphocytes in multiple sclerosis |
title_full | Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2(+ )and decreased levels of IL23R(+ )CD4(+ )T - Lymphocytes in multiple sclerosis |
title_fullStr | Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2(+ )and decreased levels of IL23R(+ )CD4(+ )T - Lymphocytes in multiple sclerosis |
title_full_unstemmed | Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2(+ )and decreased levels of IL23R(+ )CD4(+ )T - Lymphocytes in multiple sclerosis |
title_short | Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2(+ )and decreased levels of IL23R(+ )CD4(+ )T - Lymphocytes in multiple sclerosis |
title_sort | preliminary study: treatment with intramuscular interferon beta-1a results in increased levels of il-12rβ2(+ )and decreased levels of il23r(+ )cd4(+ )t - lymphocytes in multiple sclerosis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292517/ https://www.ncbi.nlm.nih.gov/pubmed/22182694 http://dx.doi.org/10.1186/1471-2377-11-155 |
work_keys_str_mv | AT kressbennettjenniferm preliminarystudytreatmentwithintramuscularinterferonbeta1aresultsinincreasedlevelsofil12rb2anddecreasedlevelsofil23rcd4tlymphocytesinmultiplesclerosis AT ehrlichgarthd preliminarystudytreatmentwithintramuscularinterferonbeta1aresultsinincreasedlevelsofil12rb2anddecreasedlevelsofil23rcd4tlymphocytesinmultiplesclerosis AT brunoashley preliminarystudytreatmentwithintramuscularinterferonbeta1aresultsinincreasedlevelsofil12rb2anddecreasedlevelsofil23rcd4tlymphocytesinmultiplesclerosis AT postjchristopher preliminarystudytreatmentwithintramuscularinterferonbeta1aresultsinincreasedlevelsofil12rb2anddecreasedlevelsofil23rcd4tlymphocytesinmultiplesclerosis AT hufenz preliminarystudytreatmentwithintramuscularinterferonbeta1aresultsinincreasedlevelsofil12rb2anddecreasedlevelsofil23rcd4tlymphocytesinmultiplesclerosis AT scottthomasf preliminarystudytreatmentwithintramuscularinterferonbeta1aresultsinincreasedlevelsofil12rb2anddecreasedlevelsofil23rcd4tlymphocytesinmultiplesclerosis |